Skip navigation
Please use this identifier to cite or link to this item: https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/134
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTroeung, L.-
dc.contributor.authorArnold-Reed, D.-
dc.contributor.authorChan She Ping-Delfos, W.-
dc.contributor.authorWatts, G. F.-
dc.contributor.authorJing, P.-
dc.contributor.authorLugonja, M.-
dc.contributor.authorBulsara, M.-
dc.contributor.authorMortley, D.-
dc.contributor.authorJames, M.-
dc.contributor.authorBrett, T.-
dc.date.accessioned2024-11-27T03:14:47Z-
dc.date.available2024-11-27T03:14:47Z-
dc.date.issued2016-06-
dc.identifier.citationHeart. 2016 Jun 1;102(11):855-61. doi: 10.1136/heartjnl-2015-308824.en
dc.identifier.urihttps://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/134-
dc.description.abstractObjective: To evaluate the performance of a new electronic screening tool (TARB-Ex) in detecting general practice patients at potential risk of familial hypercholesterolaemia (FH).Methods: Medical records for all active patients seen between 2012 and 2014 (n=3708) at a large general practice in Perth, Western Australia were retrospectively screened for potential FH risk using TARB-Ex. Electronic extracts of medical records for patients identified with potential FH risk (defined as Dutch Lipid Clinic Network Criteria (DLCNC) score ≥5) through TARB-Ex were reviewed by a general practitioner (GP) and lipid specialist. High-risk patients were recalled for clinical assessment to determine phenotypic FH diagnosis. Performance was evaluated against a manual record review by a GP in the subset of 360 patients with high blood cholesterol (cholesterol ≥7 mmol/L or low-density lipoprotein cholesterol ≥4.0 mmol/L).Results: Thirty-two patients with DLCNC score ≥5 were identified through electronic screening compared with 22 through GP manual review. Sensitivity was 95.5% (95% CI 77.2% to 99.9%), specificity was 96.7% (95% CI 94.3% to 98.3%), negative predictive accuracy was 99.7% (95% CI 98.3% to 100%) and positive predictive accuracy was 65.6% (95% CI 46.9% to 8%). Electronic screening was completed in 10 min compared with 60 h for GP manual review. 10 of 32 patients (31%) were considered high risk and recalled for clinical assessment. Six of seven patients (86%) who attended clinical assessment were diagnosed with phenotypic FH on examination.Conclusions: TARB-Ex screening is a time-effective and cost-effective method of systematically identifying potential FH risk patients from general practice records for clinical follow-up.en
dc.language.isoenen
dc.subjectGeneral Practiceen
dc.subjectHyperlipoproteinemia Type IIen
dc.subjectCholesterolen
dc.titleA new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practiceen
dc.typeArticleen
dc.contributor.mnclhdauthorJames, Matthew-
Appears in Collections:Medicine

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing